|
|
|
(State or other jurisdiction of incorporation or organization)
|
(Commission File Number)
|
(I.R.S Employer Identification No.)
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
|
|
|
|
|
|
|
|
|
|
|
Item 8.01 |
Other Events.
|
Item 9.01 |
Financial Statements and Exhibits.
|
(d)
|
Exhibits
|
Exhibit
No.
|
Description
|
|
99.1
|
Press release of Bristol-Myers Squibb Company dated February 4, 2021.
|
|
104
|
The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).
|
Exhibit
No.
|
Description
|
|
Press release of Bristol-Myers Squibb Company dated February 4, 2021.
|
||
104
|
The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).
|
BRISTOL-MYERS SQUIBB COMPANY
|
|||
Dated: February 4, 2021
|
By:
|
/s/ Katherine R. Kelly
|
|
Name:
|
Katherine R. Kelly
|
||
Title:
|
Corporate Secretary
|
||
Title of Security
|
CUSIP/ISIN
Number(s)
|
Issuer / Offeror
|
Principal
Amount
Outstanding
|
Acceptance
Priority
Level
|
Reference U.S. Treasury Security(1)
|
Bloomberg
Reference
Page
|
Fixed Spread
(basis points) (1)
|
Early
Tender
Premium(2)
|
||||||
7.150% Notes due 2023
|
110122AA6
|
Bristol Myers Squibb
|
$
|
301,532,000
|
1
|
0.125% UST due January 31, 2023
|
FIT 1
|
15
|
$
|
50
|
||||
4.000% Notes due 2023
|
110122DA3/
110122BL1/
U11009AL8
|
Bristol Myers Squibb
|
$
|
636,086,000
|
2
|
0.125% UST due August 15, 2023
|
FIT 5
|
20
|
$
|
50
|
||||
4.000% Notes due 2023
|
151020AJ3
|
Celgene
|
$
|
63,914,000
|
2
|
0.125% UST due August 15, 2023
|
FIT 5
|
20
|
$
|
50
|
Title of Security
|
CUSIP/ISIN
Number(s)
|
Issuer / Offeror
|
Principal
Amount
Outstanding
|
Acceptance
Priority
Level
|
Reference U.S. Treasury Security(1)
|
Bloomberg
Reference
Page
|
Fixed Spread
(basis points) (1)
|
Early
Tender
Premium(2)
|
||||||
3.625% Notes due 2024*
|
110122DB1/
110122BM9/
U11009AM6
|
Bristol Myers Squibb
|
$
|
882,510,000
|
1
|
0.125% UST due January 15, 2024
|
FIT 1
|
15
|
$
|
50
|
||||
3.625% Notes due 2024*
|
151020AP9
|
Celgene
|
$
|
117,490,000
|
1
|
0.125% UST due January 15, 2024
|
FIT 1
|
15
|
$
|
50
|
||||
2.900% Notes due 2024
|
110122CM8/
110122BZ0/
U11009AZ7
|
Bristol Myers Squibb
|
$
|
3,250,000,000
|
2
|
1.750% UST due July 31, 2024
|
FIT 5
|
15
|
$
|
50
|
Title of Security
|
CUSIP/ISIN
Number(s)
|
Issuer / Offeror
|
Principal
Amount
Outstanding
|
Acceptance
Priority
Level
|
Reference U.S. Treasury Security(1)
|
Bloomberg
Reference
Page
|
Fixed Spread
(basis points) (1)
|
Early
Tender
Premium(2)
|
||||||
3.875% Notes due 2025*
|
110122DC9/
110122BN7/
U11009AN4
|
Bristol Myers Squibb
|
$
|
2,379,532,000
|
1
|
0.375% UST due January 31, 2026
|
FIT 1
|
15
|
$
|
50
|
||||
3.875% Notes due 2025*
|
151020AS3
|
Celgene
|
$
|
120,468,000
|
1
|
0.375% UST due January 31, 2026
|
FIT 1
|
15
|
$
|
50
|
Title of Security
|
CUSIP/ISIN
Number(s)
|
Issuer / Offeror
|
Principal
Amount
Outstanding
|
Acceptance
Priority
Level
|
Reference U.S. Treasury Security(1)
|
Bloomberg
Reference
Page
|
Fixed Spread
(basis points) (1)
|
Early
Tender
Premium(2)
|
||||||
6.125% Notes due 2038
|
110122AQ1
|
Bristol Myers Squibb
|
$
|
226,259,000
|
1
|
1.625% UST due November 15, 2050
|
FIT 1
|
90
|
$
|
50
|
||||
5.875% Notes due 2036
|
110122AP3
|
Bristol Myers Squibb
|
$
|
286,673,000
|
2
|
1.625% UST due November 15, 2050
|
FIT 1
|
80
|
$
|
50
|
||||
6.875% Notes due 2097
|
110122AC2
|
Bristol Myers Squibb
|
$
|
86,896,000
|
3
|
1.625% UST due November 15, 2050
|
FIT 1
|
165
|
$
|
50
|
||||
5.700% Notes due 2040
|
110122DF2/
110122BR8/
U11009AR5
|
Bristol Myers Squibb
|
$
|
245,785,000
|
4
|
1.625% UST due November 15, 2050
|
FIT 1
|
90
|
$
|
50
|
||||
5.700% Notes due 2040
|
151020AF1
|
Celgene
|
$
|
4,215,000
|
4
|
1.625% UST due November 15, 2050
|
FIT 1
|
90
|
$
|
50
|
||||
5.250% Notes due 2043
|
110122DG0/
110122BS6/
U11009AS3
|
Bristol Myers Squibb
|
$
|
391,925,000
|
5
|
1.625% UST due November 15, 2050
|
FIT 1
|
85
|
$
|
50
|
||||
5.250% Notes due 2043
|
151020AL8
|
Celgene
|
$
|
8,075,000
|
5
|
1.625% UST due November 15, 2050
|
FIT 1
|
85
|
$
|
50
|
||||
4.625% Notes due 2044*
|
110122DH8/
110122BT4/
U11009AT1
|
Bristol Myers Squibb
|
$
|
976,477,000
|
6
|
1.625% UST due November 15, 2050
|
FIT 1
|
80
|
$
|
50
|
||||
4.625% Notes due 2044*
|
151020AM6
|
Celgene
|
$
|
23,523,000
|
6
|
1.625% UST due November 15, 2050
|
FIT 1
|
80
|
$
|
50
|
||||
5.000% Notes due 2045*
|
110122DJ4/
110122BU1/
U11009AU8
|
Bristol Myers Squibb
|
$
|
1,959,524,000
|
7
|
1.625% UST due November 15, 2050
|
FIT 1
|
84
|
$
|
50
|
||||
5.000% Notes due 2045*
|
151020AU8
|
Celgene
|
$
|
40,476,000
|
7
|
1.625% UST due November 15, 2050
|
FIT 1
|
84
|
$
|
50
|
||||
4.250% Notes due 2049*
|
110122CR7/
110122CD8/
U11009BD5
|
Bristol Myers Squibb
|
$
|
3,750,000,000
|
8
|
1.625% UST due November 15, 2050
|
FIT 1
|
88
|
$
|
50
|
• |
Notes may be validly withdrawn at any time at or prior to 5:00 p.m. (New York City time) on February 18, 2021, (such date and time with respect to an Offer, as the
same may be extended with respect to such Offer), but not thereafter, unless extended with respect to any Offer. Holders should not tender any Notes that they do not wish to be accepted for purchase.
|
• |
Subject to the satisfaction or waiver of the conditions of the Offers, the Acceptance Priority Procedures will operate concurrently, but separately, for the 2023 Pool
Notes, 2024 Pool Notes, 2025 Pool Notes and High Coupon Pool Notes, in each case subject to proration as described in the Offer to Purchase.
|
• |
first, if the aggregate cash purchase price (excluding the applicable
Accrued Coupon Payments) of all 2023 Pool Notes, 2024 Pool Notes, 2025 Pool Notes or High Coupon Pool Notes, as applicable, validly tendered at or prior to the applicable Early Tender Deadline by Holders does not exceed the applicable pool
maximum, then the applicable Offeror will accept all such Notes. However, if the aggregate cash purchase price (excluding the applicable Accrued Coupon Payments) of all 2023 Pool Notes, 2024 Pool Notes, 2025 Pool Notes or High Coupon Pool
Notes, as applicable, validly tendered at or prior to the applicable Early Tender Deadline by Holders exceeds the applicable pool maximum, then the Offerors will (i) accept such Notes for purchase for cash, starting at the highest acceptance
priority level (level 1) and, if there is more than one priority level, moving sequentially to each lower acceptance priority level (the lowest of which is level 2 in the case of the 2023 Pool Offers and 2024 Pool Offers and level 8 in the
case of the High Coupon Pool Offers; the 2025 Pool Offers have only one priority level), until the aggregate cash purchase price (excluding the applicable Accrued Coupon Payments) of such Notes equals the applicable pool maximum, (ii) prorate
the series of such Notes with the lowest acceptance priority level accepted for purchase for cash (including equal proration between Notes having the same priority but different Offerors) and (iii) not accept for purchase for cash (x) any
such Notes of a series with an acceptance priority level below the prorated series or (y) any 2023 Pool Notes, 2024 Pool Notes, 2025 Pool Notes or High Coupon Pool Notes, as applicable, validly tendered after the applicable Early Tender
Deadline; and
|
• |
second, if the applicable pool maximum is not exceeded at the applicable
Early Tender Deadline, the Offerors will repeat the steps described in the prior bullet with respect to all 2023 Pool Notes, 2024 Pool Notes, 2025 Pool Notes or High Coupon Pool Notes, as applicable, validly tendered after the applicable
Early Tender Deadline, but at or prior to the applicable Expiration Date, in order to determine the aggregate principal amount of such Notes that the applicable Offeror will accept for purchase in the 2023 Pool Offers, the 2024 Pool Offers,
the 2025 Pool Offers or the High Coupon Pool Offers, as applicable.
|
o |
All 2023 Pool Notes, regardless of acceptance priority level, that are validly tendered at or prior to the applicable Early Tender Deadline will have priority over
2023 Pool Notes validly tendered after the applicable Early Tender Deadline and at or prior to the applicable Expiration Date.
|
o |
All 2024 Pool Notes, regardless of acceptance priority level, that are validly tendered at or prior to the applicable Early Tender Deadline will have priority over
2024 Pool Notes validly tendered after the applicable Early Tender Deadline and at or prior to the applicable Expiration Date.
|
o |
All 2025 Pool Notes, regardless of acceptance priority level, that are validly tendered at or prior to the applicable Early Tender Deadline will have priority over
2025 Pool Notes validly tendered after the applicable Early Tender Deadline and at or prior to the applicable Expiration Date.
|
o |
All High Coupon Pool Notes, regardless of acceptance priority level, that are validly tendered at or prior to the applicable Early Tender Deadline will have priority
over High Coupon Pool Notes validly tendered after the applicable Early Tender Deadline and at or prior to the applicable Expiration Date
|
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M3;8QY)C&S'TZ58HH JV.G66GHR6%I;VJ,
L]]MK6G4D"&*88>#*/BZ
M@)>:NH/!H)V-;J&<")50;V7S[ 7!)G\$Q_ >S@+Q]\_[L77O05L@VBEDUV *
M8W[(;'?VM(3G#8J290S5M@6!,S-/3,B61F1G(++3?2NR\^H'<_N8\.;"2A/,
M0'R:.#.^8JR%PQP?],VI4EL6\LTIL\Q/@,6=XYS/%!WT&"<'291C\_)DPWJ!PU4"4S9,><488D_C=(9)DDT)
MU0%/DR<>3Z_;Z75>9]&4T^U&MR20 +'E!GW273><_F,(G.KK1L3;.$/A:4.-_>334E\:GREXT
MK==/[#^8ZB (0)*)() 7+]>-TWG!%.[,^BV=*6>^ Y% $9! 5%,^%@%.+ZTC
M 9&D4+$*!%#YUA))GB=]B$8&=RA+HE A$4' ,2[/DT$7T?G"GC8"4\0P=Y.(
MI0I+5D0L,^$.Q(6Y3M^B/D]OPKAEHI\NXL,\&7]*RU&*;R;N6C9'$P-5DVP:
MX-Y!6?'AMIJC2")EXB9>"-25EB96Q<;'Y$>'V8#',[%?U0V%;O:.?CD_NS[]
M@*ZNCZ]/KPX[IO+,'+8+.ET&^M7IR2^79]=GIU?H^/P#.OWUY*?C\Q]/TH:LD&AKFS\I6Q;\/B026B',D4\US:#W,PO@&G7[X\?@R"$%Z;C+TY?("
M'C7RVG:;M*VIUB?)8)2&-[T<
53V3$3&,H6G1*Q_FO22%":FFG(@7?H50TTX1)51XON42
MUUS($6!N,3?P/4$"YOK8"QZ=(K%2-2_J_15)#3 +DRGX;H_LK?$8-ST=LBV-
MO_H7TQY\ &;E^9>UJ%NB^I^!<-NR"FU0$<41]$5>#GX$JL=I9L
MUNQ^,&8W@9LD$SFR%\%PJZ51_HVK7W.&L_O!5MNYA.:-":>\P&:TT:3>1/1?KD/YA(T)
MG&XIXQOT21B3%@\N:QXM68!M +DX\!H,DX8GNLMB09TBF *,!;%H"6BM:P;-
M5A1&;0B)LLJH$5Z'?A9VPW=C<<(:XKO83ON2RM33CRQK8
M2E@C;AZ&/%M'Q@]NN-9(GQTG_PT'J!CP0_%;\*Q.E:J&<-7$F)F'D_.UQ:HU
M=TOJ9&,\ZM:P3O6OUHZ0 ,Q&R&3S2>2]B>G!C/='/A]-67\ZF Q&S.OUN>L/
M>C,V];K=HP0$!J/V,0CJ^-A$]&6=(,(=FOATMH=6UR8CJR4V*0+,>_'(:%N3
MW5Y$@5ZOVT75'*/;6UI%EY0YHC-'T7
&TSVL[=SOD_=)@@
M0IN.B!MZQ3T1C=7O8JVK[I2BBO*EK\YKA'/HRLN:G'_F,"F.$Q(=I(9EISKZ
MI_#[)-)"<>F)S_0\1!;T&SRWE"0:K/DPA>E)&\(E%>(FJ^#F0K/4V.B;B*
M+#5BDF3 ,4VP7,&A54M<$:N$QY$8S6@8UD8Y+(%